RE:RE:RE:RE:GOLDYour post has some real info but wow are you off on the order requirements. At present we have a conpany with basically zero revenue. So yes i agree at present over valued. But is based on the future of sona which currently is focused on the covid 19 antigen test. Manufacturing is already being set to ramp up. So here is a little math for you: 40 million test at 35 a test with 75% profit (conservative as i understand nomal margin is 85%, but granted any number is currently a guess). But at 75% that represents a one time bonus of $17 per share. This is all for the one test. This does not take into account that the company had 5 other tests being trialed before covid happened. So at present overvalued, perhaps. But IMO not for long.